The U.S. Food and Drug Administration approved Johnson & Johnson’s drug Darzalex Faspro as the first treatment for adults with high-risk smoldering multiple myeloma, a precursor to the blood cancer. The decision marks a shift toward earlier intervention in a disease that typically progresses to active multiple myeloma. The approval is based on results from the Phase 3 AQUILA trial, which compared Darzalex Faspro—a subcutaneous formulation of daratumumab combined with hyaluronidase—to stan...